<DOC>
	<DOCNO>NCT02305654</DOCNO>
	<brief_summary>This international phase III trial , Bayesian design , incorporate two sequential randomisation . It efficiently examine series question routinely arise sequence treatment . The study design evolve lengthy international consultation enable u build consensus question arise current knowledge practice . It enable potential randomisation majority patient inguinal lymph node metastasis provide data inform future clinical decision . InPACT-neoadjuvant patient stratified disease burden assess radiological criterion . Treatment option define accord disease burden stratum . Treatment allocate randomisation . Patients may allocate one three initial treatment : A. standard surgery ( ILND ) ; B. neoadjuvant chemotherapy follow standard surgery ( ILND ) ; C. neoadjuvant chemoradiotherapy follow standard surgery ( ILND ) . After ILND , patient define low high risk recurrence base histological interpretation ILND specimen . Patients high risk relapse eligible InPACT-pelvis , randomise either : P. prophylactic PLND Q. prophylactic PLND</brief_summary>
	<brief_title>International Penile Advanced Cancer Trial ( International Rare Cancers Initiative Study )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>1 . Written inform consent 2 . Measurable disease determine RECIST ( version 1.1 ) criterion ; 3 . Histologicallyproven squamous cell carcinoma penis , 4 . Stage : T , N1 ( i.e . palpable mobile unilateral inguinal lymph node ) , M0 ; T , N2 ( i.e . palpable mobile multiple bilateral inguinal lymph node ) , M0 ; T , N3 ( i.e . fix inguinal nodal mass pelvic lymphadenopathy ) , M0 5 . Performance Status ECOG 0 , 1 2 . 1 . Pure verrucous carcinoma penis , 2 . Nonsquamous malignancy penis , 3 . Squamous carcinoma urethra , 4 . Stage M1 , 5 . Previous chemotherapy chemoradiotherapy , 6 . Concurrent malignancy ( SCC Basal Cell Carcinoma nonpenile skin ) require surgical nonsurgical treatment last 3 year .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Penis cancer</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Chemoradiotherapy</keyword>
	<keyword>Surgery</keyword>
	<keyword>Phase III</keyword>
</DOC>